CO5700790A2 - Composiciones de vacuna que comprenden una interleucina 18 y sistema de adyuvante de saponina - Google Patents
Composiciones de vacuna que comprenden una interleucina 18 y sistema de adyuvante de saponinaInfo
- Publication number
- CO5700790A2 CO5700790A2 CO06034535A CO06034535A CO5700790A2 CO 5700790 A2 CO5700790 A2 CO 5700790A2 CO 06034535 A CO06034535 A CO 06034535A CO 06034535 A CO06034535 A CO 06034535A CO 5700790 A2 CO5700790 A2 CO 5700790A2
- Authority
- CO
- Colombia
- Prior art keywords
- saponina
- interleucine
- vaccine compositions
- assistant system
- mammal
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000000975 bioactive effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 1
- 229930182490 saponin Natural products 0.000 abstract 1
- 150000007949 saponins Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
1.- Un método para aumentar la respuesta inmune a un antígeno en un mamífero, en donde el método comprende administrar al mamífero una cantidad segura y efectiva de 1) un polipéptido IL-18 ó un fragmento bioactivo o variante del mismo, y 2) una composición inmunogénica que comprende un antígeno o derivado inmunogénico del mismo y un adyuvante de saponina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0323965.4A GB0323965D0 (en) | 2003-10-13 | 2003-10-13 | Immunogenic compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5700790A2 true CO5700790A2 (es) | 2006-11-30 |
Family
ID=29559205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO06034535A CO5700790A2 (es) | 2003-10-13 | 2006-04-07 | Composiciones de vacuna que comprenden una interleucina 18 y sistema de adyuvante de saponina |
Country Status (17)
Country | Link |
---|---|
US (1) | US20070212329A1 (es) |
EP (1) | EP1687025A1 (es) |
JP (1) | JP2007508272A (es) |
KR (1) | KR20070054136A (es) |
CN (1) | CN1889977A (es) |
AU (1) | AU2004283457A1 (es) |
BR (1) | BRPI0415304A (es) |
CA (1) | CA2541695A1 (es) |
CO (1) | CO5700790A2 (es) |
GB (1) | GB0323965D0 (es) |
IL (1) | IL174544A0 (es) |
IS (1) | IS8374A (es) |
MA (1) | MA28149A1 (es) |
NO (1) | NO20061912L (es) |
RU (1) | RU2006111847A (es) |
WO (1) | WO2005039634A1 (es) |
ZA (1) | ZA200602950B (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2399148A1 (en) * | 2000-02-10 | 2001-08-16 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
US7727561B2 (en) | 2001-08-31 | 2010-06-01 | Pacific Arrow Limited | Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof |
US7524824B2 (en) * | 2003-09-04 | 2009-04-28 | Pacific Arrow Limited | Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof |
WO2004014322A2 (en) * | 2002-08-12 | 2004-02-19 | Dynavax Technologies Corporation | Immunomodulatory compositions, methods of making, and methods of use thereof |
CN101242850B (zh) * | 2003-10-09 | 2013-03-20 | 太平洋艾瑞有限公司 | 文冠果的提取物和从提取物分离出的化合物的组成,功能和应用,以及它们的制备方法 |
US8614197B2 (en) * | 2003-10-09 | 2013-12-24 | Pacific Arrow Limited | Anti-tumor compounds with angeloyl groups |
US7514412B2 (en) * | 2003-10-09 | 2009-04-07 | Pacific Arrow Limited | Anticancer biangeloyl saponins |
US7488753B2 (en) * | 2003-10-09 | 2009-02-10 | Pacific Arrow Limited | Composition comprising triterpene saponins and compounds with angeloyl functional group, methods for preparing same and uses thereof |
US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
DE102004022200B4 (de) | 2004-05-05 | 2006-07-20 | Actinium Pharmaceuticals, Inc. | Radium-Target sowie Verfahren zu seiner Herstellung |
US9382285B2 (en) | 2004-09-07 | 2016-07-05 | Pacific Arrow Limited | Methods and compounds for modulating the secretion or expression of adhesion proteins or angiopoietins of cells |
US8735558B2 (en) * | 2005-02-14 | 2014-05-27 | Pacific Arrow Limited | Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof |
US8586719B2 (en) * | 2005-04-27 | 2013-11-19 | Pacific Arrow Limited | Triterpenes for modulating gene expression and cell membrane, and as antiprotozoal agents |
DE102006008023B4 (de) | 2006-02-21 | 2008-05-29 | Actinium Pharmaceuticals, Inc. | Verfahren zum Reinigen von 225Ac aus bestrahlten 226Ra-Targets |
JP5197603B2 (ja) | 2006-09-08 | 2013-05-15 | アクチニウム ファーマシューティカルズ,インコーポレイティド | 種々の供給源からのラジウムの精製方法 |
US7709010B2 (en) * | 2007-03-09 | 2010-05-04 | Merck Sharp & Dohme Corp. | Papillomavirus vaccine compositions |
ES2588705T3 (es) * | 2007-09-27 | 2016-11-04 | Immunovaccine Technologies Inc. | Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo |
US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
BRPI0905725B8 (pt) | 2008-01-11 | 2021-05-25 | Univ Emory | vacina e embalagem farmacêutica |
CA2723918C (en) * | 2008-06-05 | 2018-01-09 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
LT3056214T (lt) * | 2008-06-27 | 2019-06-10 | Zoetis Services Llc | Naujos adjuvantų kompozicijos |
TWI351288B (en) * | 2008-07-04 | 2011-11-01 | Univ Nat Pingtung Sci & Tech | Cpg dna adjuvant in avian vaccines |
CN102215861B (zh) * | 2009-06-19 | 2014-10-08 | 艾金株式会社 | 宫颈癌疫苗 |
US9434677B2 (en) | 2009-07-16 | 2016-09-06 | Pacific Arrow Limited | Natural and synthetic compounds for treating cancer and other diseases |
US20120277308A1 (en) | 2010-07-16 | 2012-11-01 | Pacific Arrow Limited | compounds for treating cancer and other diseases |
US9499577B2 (en) | 2009-07-16 | 2016-11-22 | Pacific Arrow Limited | Natural and synthetic compounds for treating cancer and other diseases |
UA110103C2 (uk) * | 2010-01-27 | 2015-11-25 | Ґлаксосмітклайн Байолоджікалз С.А. | Модифікований туберкульозний антиген |
WO2011148356A1 (en) * | 2010-05-28 | 2011-12-01 | Coley Pharmaceutical Group, Inc. | Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules |
GB201016471D0 (en) * | 2010-09-30 | 2010-11-17 | Isis Innovation | Viral vector immunogenic compositions |
RU2482866C2 (ru) * | 2010-10-07 | 2013-05-27 | Общество с ограниченной ответственностью "Аллоферон" | Способ лечения папилломавирусных инфекций, реализуемый через индукцию интерлейкина-18 |
SG11201401177WA (en) | 2011-10-06 | 2014-04-28 | Immunovaccine Technologies Inc | Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof |
GB201205361D0 (en) * | 2012-03-27 | 2012-05-09 | Univ Nottingham Trent | Breast cancer assay |
CA2897084C (en) * | 2013-01-04 | 2019-07-16 | Cheng Der Tony Yu | Vaccines with higher carbohydrate antigen density and novel saponin adjuvant |
CA2962799A1 (en) * | 2014-10-01 | 2016-04-07 | The Trustees Of The University Of Pennsylvania | Vaccines having an antigen and interleukin-21 as an adjuvant |
US10456459B2 (en) | 2015-07-20 | 2019-10-29 | Zoetis Services Llc | Liposomal adjuvant compositions |
GB201522329D0 (en) * | 2015-12-17 | 2016-02-03 | Glaxosmithkline Biolog S A And Inst Nat De La Sante Et De La Rech Medicale Inserm And Université Pie | Use of adjuvants for the prevention and/or treatment of autoimmune diseases |
CN110461355B (zh) * | 2016-10-31 | 2023-06-09 | 艾金株式会社 | 包含免疫调控剂和阳离子脂质体的免疫增强的组合物及其用途 |
CN107952069A (zh) * | 2017-11-24 | 2018-04-24 | 长春百克生物科技股份公司 | 重组疫苗及其应用 |
EP3669890A1 (en) * | 2018-12-18 | 2020-06-24 | Croda International PLC | Filamentous nanoparticles having vaccine adjuvant effect |
EP4074335A4 (en) * | 2019-12-13 | 2024-09-04 | Grand Theravac Life Science Nanjing Co Ltd | IMMUNOSTIMULATORY COMPOSITION AND ITS USE |
WO2022034555A1 (en) * | 2020-08-13 | 2022-02-17 | Janssen Biopharma, Inc. | Polynucleotide constructs and uses thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0671948B1 (en) * | 1992-06-25 | 1997-08-13 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
US5869445A (en) * | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6355256B1 (en) * | 1994-09-30 | 2002-03-12 | Ludwig Institute For Cancer Research | Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof |
GB9712347D0 (en) * | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
WO1999056775A1 (en) * | 1998-05-07 | 1999-11-11 | Akzo Nobel N.V. | Use of interleukin-18 as vaccine adjuvant |
US6562798B1 (en) * | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
ES2228497T3 (es) * | 1999-04-19 | 2005-04-16 | Glaxosmithkline Biologicals S.A. | Composicion adyuvante que comprende saponina y un oligonucleotido inmunoestimulante. |
US6843987B2 (en) * | 2000-02-02 | 2005-01-18 | Schering Corporation | Mammalian cytokines; receptors; related reagents and methods |
CA2399148A1 (en) * | 2000-02-10 | 2001-08-16 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
-
2003
- 2003-10-13 GB GBGB0323965.4A patent/GB0323965D0/en not_active Ceased
-
2004
- 2004-10-11 WO PCT/EP2004/011620 patent/WO2005039634A1/en active Application Filing
- 2004-10-11 KR KR1020067009283A patent/KR20070054136A/ko not_active Application Discontinuation
- 2004-10-11 BR BRPI0415304-9A patent/BRPI0415304A/pt not_active Application Discontinuation
- 2004-10-11 AU AU2004283457A patent/AU2004283457A1/en not_active Abandoned
- 2004-10-11 CA CA002541695A patent/CA2541695A1/en not_active Abandoned
- 2004-10-11 EP EP04790465A patent/EP1687025A1/en not_active Withdrawn
- 2004-10-11 US US10/575,838 patent/US20070212329A1/en not_active Abandoned
- 2004-10-11 JP JP2006530155A patent/JP2007508272A/ja active Pending
- 2004-10-11 RU RU2006111847/13A patent/RU2006111847A/ru not_active Application Discontinuation
- 2004-10-11 CN CNA2004800363071A patent/CN1889977A/zh active Pending
-
2006
- 2006-03-23 IL IL174544A patent/IL174544A0/en unknown
- 2006-03-27 IS IS8374A patent/IS8374A/is unknown
- 2006-04-07 CO CO06034535A patent/CO5700790A2/es not_active Application Discontinuation
- 2006-04-11 ZA ZA200602950A patent/ZA200602950B/xx unknown
- 2006-04-28 NO NO20061912A patent/NO20061912L/no not_active Application Discontinuation
- 2006-05-04 MA MA29002A patent/MA28149A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
IL174544A0 (en) | 2006-08-01 |
CN1889977A (zh) | 2007-01-03 |
US20070212329A1 (en) | 2007-09-13 |
WO2005039634A1 (en) | 2005-05-06 |
IS8374A (is) | 2006-03-27 |
EP1687025A1 (en) | 2006-08-09 |
ZA200602950B (en) | 2007-09-26 |
MA28149A1 (fr) | 2006-09-01 |
BRPI0415304A (pt) | 2006-12-05 |
KR20070054136A (ko) | 2007-05-28 |
RU2006111847A (ru) | 2007-11-20 |
AU2004283457A1 (en) | 2005-05-06 |
GB0323965D0 (en) | 2003-11-19 |
CA2541695A1 (en) | 2005-05-06 |
NO20061912L (no) | 2006-06-02 |
JP2007508272A (ja) | 2007-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5700790A2 (es) | Composiciones de vacuna que comprenden una interleucina 18 y sistema de adyuvante de saponina | |
NO20082472L (no) | Vaksinesammensetninger omfattende en saponin adjuvant | |
CY1112572T1 (el) | Εμβολια γριπης που περιλαμβανουν συνδυασμους σωματιδιακων ανοσοενισχυτικων και ανοσοδιεγερτες | |
AR035586A1 (es) | Composicion de vacuna, equipo, metodos para incrementar la respuesta inmune, uso de un derivado de 1h-imidazo(4,5-c)quinolin-4-amina en la fabricacion de un medicamento, y combinacion de componentes para la administracion separada, secuencial o concomitante para el uso en la vacunacion de adn | |
ES2157447T3 (es) | Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio. | |
AR040204A1 (es) | Composicion de vacuna meningococica multivalente | |
PT1284998E (pt) | Eptideos imunogenicos sinteticos mas nao-amiloidogenicos homologos a beta-amiloides, destinados a induzir uma reaccao imunitaria contra os beta-amiloides e os depositos amiloides | |
PT1187629E (pt) | Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador | |
MX2008013993A (es) | Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular. | |
BRPI0510430A (pt) | composições e métodos para vacinação mucosal | |
CO5700788A2 (es) | Composiciones y metodos para inmunoterapia especifica de wt1 | |
NO20070551L (no) | Vaksinesammensetninger og fremgangsmater for behandling av koronavirus infeksjon. | |
TW200722101A (en) | Novel composition | |
FR2814958B1 (fr) | Composition vaccinale | |
AR053711A1 (es) | Combinacion de vacunas para circovirus porcina y helicobacter y metodos de utilizacion | |
DK1898948T3 (da) | Polyriboinosinsyre-polyribocytidylsyre-baseret adjuvans | |
SE0202110D0 (sv) | Iscom preparation and use thereof | |
ES2195169T3 (es) | Vacunas contra calmidias y composiciones inmunogenicas que contienen un antigeno de membrana externa y metodos para su preparacion. | |
WO2006136460A8 (en) | New adjuvant | |
BRPI0113155C1 (pt) | métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b | |
EP1471936A4 (en) | HIV VACCINE AND METHOD OF USE | |
UA90493C2 (ru) | Альфа-тимозиновые пептиды как адьюванты противораковых вакцин | |
AR053661A1 (es) | Peptido para entregar vacunas via mucosas | |
AR054259A1 (es) | Vacuna contra virus de papiloma humano (hpv) | |
CO6341568A2 (es) | Composicion inmunologica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |